THE LANCER NEUROLOGY

• [Comment] New therapies for Pompe disease: are we closer to a cure? December 1, 2021 Rosa Puertollano, Nina Raben
• [Comment] Paediatric multiple sclerosis: a lesson from TERIKIDS December 1, 2021 Maria Pia Sormani, Emmanuelle Waubant
• [Corrections] Correction to Lancet Neurol 2019; 18: 56–87 December 1, 2021
• [Editorial] The International Brain Initiative: collaboration in progress December 1, 2021 The Lancet Neurology
• [In Context] Trials for neurodegenerative diseases: time to innovate December 1, 2021 Arpan R Mehta, Jeremy Chataway, Suvankar Pal, Mahesh K B Parmar, Siddharthan Chandran
• [Comment] 20th Anniversary photography competition: neurology for zoomers December 1, 2021 Elena Becker-Barroso, Laura Hart, Heather Brown, Sarah Passey
• [In Context] Gabriel Bsteh December 1, 2021
• [Articles] Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial December 1, 2021 Jordi Diaz-Manera, Priya S Kishnani, Hani Kushlaf, Shafeeq Ladha, Tahseen Mozaffar, Volker Straub, Antonio Toscano, Ans T van der Ploeg, Kenneth I Berger, Paula R Clemens, Yin-Hsiu Chien, John W Day, Sergey Illarioshkin, Mark Roberts, Shahram Attarian, Joao Lindolfo Borges, Francoise Bouhour, Young Chul Choi, Sevim Erdem-Ozdamar, Ozlem Goker-Alpan, Anna Kostera-Pruszczyk, Kristina An Haack, Christopher Hug, Olivier Huynh-Ba, Judith Johnson, Nathan Thibault, Tianyue Zhou, Mazen M Dimachkie, Benedikt Schoser, COMET Investigator Group
• [Corrections] Correction to Lancet Neurol 2021; 20: 1038–47 December 1, 2021
• [Corrections] Correction to Lancet Neurol 2018; 17: 954–76 December 1, 2021